You have free access to this content

Cancer

Cover image for Cancer

1 June 2007

Volume 109, Issue 11

Pages 2157–2386

  1. Commentary

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      Food and drug administration expanded access to treatment : Implications for oncology patients (pages 2157–2160)

      Ralph S. Freedman and Maurie Markman

      Version of Record online: 20 APR 2007 | DOI: 10.1002/cncr.22681

      On December 14, 2006, the FDA published simultaneously in the Federal Register their proposed rules amending regulations for expanded access to investigational drugs and for charging patients for investigational drugs. These proposed rules, if approved, could have important implications for patients, providers, and for Pharma.

  2. Review Articles

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer (pages 2161–2170)

      Xianglin L. Du, Tamra E. Meyer and Luisa Franzini

      Version of Record online: 23 APR 2007 | DOI: 10.1002/cncr.22664

      • original image
      • original image

      The results from this meta-analysis of 10 studies showed that racial disparities in survival for colon cancer between African Americans and Caucasians were only marginally significant after adjusting for socioeconomic factors and treatment.

    2. You have free access to this content
      Current and emerging treatment options in chronic myeloid leukemia (pages 2171–2181)

      Elias Jabbour, Jorge E. Cortes, Francis J. Giles, Susan O'Brien and Hagop M. Kantarjian

      Version of Record online: 12 APR 2007 | DOI: 10.1002/cncr.22661

      • original image

      In this review, recent clinical data are summarized for therapies available to treat chronic myeloid leukemia, including imatinib and dasatinib. Other treatment options, including therapies currently in development, are also described.

    3. You have free access to this content
      Infectious complications of monoclonal antibodies used in cancer therapy : A systematic review of the evidence from randomized controlled trials (pages 2182–2189)

      Petros I. Rafailidis, Ourania K. Kakisi, Konstantinos Vardakas and Matthew E. Falagas

      Version of Record online: 11 APR 2007 | DOI: 10.1002/cncr.22666

      • original image

      This systematic review suggests that comparable infectious complications are observed in patients with non-Hodgkin lymphoma when rituximab is added to a chemotherapy regimen compared with the administration of the chemotherapy regimen alone, with the exception of patients who are positive for the human immunodeficiency virus. Trastuzumab, which has a clear benefit in the treatment of breast cancer patients, appears to cause a small increase in Grade III/IV infectious complications without an increase in infection-related death.

  3. Original Articles

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver (pages 2190–2196)

      Luis H. Camacho, Razelle Kurzrock, Alex Cheung, Diane F. Barber, Sanjay Gupta, David C. Madoff, Michael J. Wallace, E. Edmund Kim, Steven A. Curley, Gabriel N. Hortobagyi and Giora Mavligit

      Version of Record online: 26 APR 2007 | DOI: 10.1002/cncr.22672

      • original image

      Hepatic arterial administration of paclitaxel at doses of 200 mg/m2 as 24-hour, continuous infusions every month to treat patients with metastatic breast carcinoma that involved the liver was safe and well tolerated. This approach may result in substantial tumor reduction, allowing for surgical resection of residual disease. Previous systemic taxane therapy did not hamper the potential efficacy of this approach.

    2. You have free access to this content
      Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy : Results of a retrospective analysis (pages 2197–2204)

      Marc Debled, Gaëtan MacGrogan, Véronique Brouste, Simone Mathoulin-Pelissier, Michel Durand and Louis Mauriac

      Version of Record online: 20 APR 2007 | DOI: 10.1002/cncr.22667

      In postmenopausal women with breast cancer who were receiving adjuvant tamoxifen therapy, lymph node status and modified Scarff-Bloom-Richardson grade 3 were the only significant predictive factors of early recurrence. In a low-risk subset of patients with lymph node-negative and/or grade 1 tumors, a sequential strategy with tamoxifen for 2 or 3 years followed by an aromatase inhibitor seemed to be the preferable option.

    3. You have free access to this content
      Effect of mammographic service screening on stage at presentation of breast cancers in Sweden (pages 2205–2212)

      Swedish Organised Service Screening Evaluation Group

      Version of Record online: 30 APR 2007 | DOI: 10.1002/cncr.22671

      • original image
      • original image
      • original image

      Screening has significantly and substantially reduced the rates of larger tumors and lymph node-positive breast cancer in Sweden, and the magnitude of the reduction is consistent with the reduction in breast cancer mortality.

    4. Gastrointestinal Disease
      You have free access to this content
      Cost-effectiveness of colorectal cancer screening with computed tomography colonography : The impact of not reporting diminutive lesions (pages 2213–2221)

      Perry J. Pickhardt, Cesare Hassan, Andrea Laghi, Angelo Zullo, David H. Kim and Sergio Morini

      Version of Record online: 23 APR 2007 | DOI: 10.1002/cncr.22668

      • original image
      • original image
      • original image
      • original image

      Prior cost-effectiveness models analyzing computed tomography colonography (CTC) screening have assumed that patients with lesions measuring ≤5 mm will be referred to optical colonoscopy for polypectomy. However, consensus guidelines for CTC recommend reporting only those polyps that are ≥6 mm in size. The purpose of the current study was to assess the potential harms, benefits, and cost-effectiveness of CTC screening without the reporting of diminutive lesions compared with other screening strategies.

    5. You have free access to this content
      Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer (pages 2222–2228)

      Scott D. Ramsey, Nadia Howlader, Ruth Etzioni, Martin L. Brown, Joan L. Warren and Polly Newcomb

      Version of Record online: 4 APR 2007 | DOI: 10.1002/cncr.22673

      Endoscopic surveillance is recommended and widely practiced after definitive treatment for localized colorectal cancer, yet there is little evidence supporting its benefit. In a retrospective case–control study using Surveillance, Epidemiology, and End Results program–Medicare records, the authors found that surveillance endoscopy does not appear to influence colorectal cancer–specific mortality in patients age >65 years who are diagnosed with localized and regionalized colorectal cancer.

    6. Genitourinary Disease
      You have free access to this content
      Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients (pages 2229–2238)

      Ravishankar Jayadevappa, Jerry C. Johnson, Sumedha Chhatre, Alan J. Wein and S. Bruce Malkowicz

      Version of Record online: 18 APR 2007 | DOI: 10.1002/cncr.22675

      Racial and ethnic variation in patient-reported outcomes such as health-related quality of life (HRQoL) and satisfaction with care are understudied in elderly prostate cancer patients. Our prospective cohort study of 214 elderly (aged ≥65 years) men with newly diagnosed prostate cancer showed that African-American elderly had poorer outcomes and took longer to return to baseline HRQoL.

    7. You have free access to this content
      Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer (pages 2239–2247)

      Mark S. Litwin, John L. Gore, Lorna Kwan, Judson M. Brandeis, Steve P. Lee, H. Rodney Withers and Robert E. Reiter

      Version of Record online: 23 APR 2007 | DOI: 10.1002/cncr.22676

      • original image
      • original image
      • original image
      • original image

      Quality of life domains are differentially affected by various treatments for localized prostate cancer. This prospective, longitudinal cohort study illustrates that urinary control and sexual function are better after radiation, although nerve-sparing surgery diminishes these differences among potent men undergoing prostatectomy. Brachytherapy causes more urinary obstructive and irritative symptoms, whereas both forms of radiation cause more bowel dysfunction than surgery.

    8. You have free access to this content
      Evidence-based guidelines for following stage 1 seminoma (pages 2248–2256)

      Jarad M. Martin, Tony Panzarella, Daniel R. Zwahlen, Peter Chung and Padraig Warde

      Version of Record online: 16 APR 2007 | DOI: 10.1002/cncr.22674

      • original image
      • original image

      Evidence-based guidelines for the follow-up schedule for each management strategy following orchiectomy for stage 1 seminoma have been developed from a systematic review of the literature. These recommendations are based on the risk of relapse and offer the possibility of maximal patient convenience and optimal healthcare resource allocation without compromising disease control.

    9. You have free access to this content
      Prognostic relevance of the mTOR pathway in renal cell carcinoma : Implications for molecular patient selection for targeted therapy (pages 2257–2267)

      Allan J. Pantuck, David B. Seligson, Tobias Klatte, Hong Yu, John T. Leppert, Laurence Moore, Timothy O'Toole, Jay Gibbons, Arie S. Belldegrun and Robert A. Figlin

      Version of Record online: 17 APR 2007 | DOI: 10.1002/cncr.22677

      • original image
      • original image
      • original image
      • original image
      • original image

      Components of the mTOR pathway (PTEN, pAkt, p27, and pS6) were significantly associated with pathological features and survival of patients with renal cell carcinoma. Not all types of renal cell carcinoma seem to be equally amenable to mTOR targeted therapy.

    10. Head and Neck
      You have free access to this content
      Ultrasound-guided transcutaneous Tru-Cut biopsy to diagnose laryngopharyngeal masses : A pilot study (pages 2268–2272)

      Mohssen Ansarin, Elvio De Fiori, Lorenzo Preda, Fausto Maffini, Roberto Bruschini, Luca Calabrese, Barbara A. Jereczek-Fossa, Fausto Chiesa and Massimo Bellomi

      Version of Record online: 10 APR 2007 | DOI: 10.1002/cncr.22679

      • original image
      • original image
      • original image
      • original image

      Transcutaneous ultrasound-guided Tru-Cut biopsy performed under local anesthesia was found to successfully diagnose bulky/recurrent laryngopharyngeal masses in 9 of 10 patients, with no morbidity noted. This diagnostic method is promising for patients who are contraindicated for general anesthesia.

    11. Hematologic Malignancies
      You have free access to this content
      Limited feasibility of double transplant in multiple myeloma : Results of a multicenter study on 153 patients aged <65 years (pages 2273–2278)

      Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, Emilio Paolo Alessandrino, Roberto Cairoli, Enrica Morra, Mario Lazzarino and on Behalf of the HOST Group

      Version of Record online: 17 APR 2007 | DOI: 10.1002/cncr.22660

      • original image
      • original image
      • original image
      • original image

      Although high-dose therapy is considered a standard therapy for younger patients with multiple myeloma (MM), the advantages of performing a second transplant remain debated. Taking into account the limited advantage of double transplants observed, the complexity of the program, the high percentage of dropouts, and the additional costs of a second transplant, the study favors single transplant programs for the treatment of younger MM patients.

    12. You have free access to this content
      Clinical correlates of JAK2V617F allele burden in essential thrombocythemia (pages 2279–2284)

      Jaya Kittur, Ryan A. Knudson, Terra L. Lasho, Christy M. Finke, Naseema Gangat, Alexandra P. Wolanskyj, Chin-Yang Li, Wenting Wu, Rhett P. Ketterling, Animesh Pardanani and Ayalew Tefferi

      Version of Record online: 17 APR 2007 | DOI: 10.1002/cncr.22663

      • original image

      Allele-specific, quantitative polymerase chain reaction analysis for JAK2V617F was performed in 176 patients with essential thrombocythemia using genomic DNA from archived bone marrow. JAK2V617F was detected in 96 patients (55%), in whom mutant allele burden ranged from 1% to 100% (median, 6.3%). The presence of JAK2V617F was significantly associated with higher hemoglobin level, lower platelet count, higher leukocyte count, increased incidence of venous thrombosis occurring after diagnosis, and older age at diagnosis. All but age retained significance in multivariable analysis. In addition, JAK2V617F allele burden was shown to impart additional phenotypic effects.

    13. You have free access to this content
      Efficacy and safety of bortezomib in patients with plasma cell leukemia (pages 2285–2290)

      Pellegrino Musto, Fausto Rossini, Francesca Gay, Vincenzo Pitini, Tommasina Guglielmelli, Giovanni D'Arena, Felicetto Ferrara, Nunzio Filardi, Roberto Guariglia, Antonio Palumbo and for the GISMM, GISL, and GIMEMA Cooperative Groups, Italy

      Version of Record online: 27 APR 2007 | DOI: 10.1002/cncr.22700

      • original image

      Bortezomib induced an overall response rate of 92% in 12 patients with plasma cell leukemia (PCL). The median progression-free survival was 8 months (range, 5 to >21 months) and toxicity was acceptable. Bortezomib, employed alone or in combination with other drugs, could contribute toward improving the usually poor prognosis of patients with PCL.

    14. You have free access to this content
      Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia (pages 2291–2298)

      Tait D. Shanafelt, Thomas Lin, Susan M. Geyer, Clive S. Zent, Nelson Leung, Brian Kabat, Deborah Bowen, Michael R. Grever, John C. Byrd and Neil E. Kay

      Version of Record online: 18 MAY 2007 | DOI: 10.1002/cncr.22662

      • original image

      The pentostatin, cyclophosphamide, and rituximab regimen was well tolerated and efficacious for elder patients and individuals with a creatinine clearance ≤70. These findings suggest pentostatin, cyclophosphamide, and rituximab may be a good therapeutic option for elderly patients and those with modestly decreased renal function.

    15. Lung Disease
      You have free access to this content
      Loss of heterozygosity and human telomerase reverse transcriptase (hTERT) expression in bronchial mucosa of heavy smokers (pages 2299–2307)

      Linda Capkova, Marketa Kalinova, Lenka Krskova, Daniela Kodetova, Frantisek Petrik, Martin Trefny, Jaromir Musil and Roman Kodet

      Version of Record online: 11 APR 2007 | DOI: 10.1002/cncr.22683

      • original image
      • original image
      • original image
      • original image

      In this study, the presence of molecular changes in selected chromosomal regions in comparison with the histological appearance was determined. One hundred twenty-two bronchial biopsies were obtained by a combination of white-light and autofluorescence bronchoscopy from heavy smokers with COPD. Findings indicated that presence of LOH and expression of hTERT mRNA represent early events in lung carcinogenesis, as both were detected in precancerous lesions and in normal epithelium of heavy smokers.

    16. Neuro-Oncology
      You have free access to this content
      Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy (pages 2308–2314)

      Stephanie E. Combs, Christoph Thilmann, Peter E. Huber, Angelika Hoess, Jürgen Debus and Daniela Schulz-Ertner

      Version of Record online: 27 APR 2007 | DOI: 10.1002/cncr.22703

      • original image
      • original image

      Long-term outcome of fractionated stereotactic radiotherapy for craniopharyngiomas is excellent with regard to local control as well as treatment-related side effects, with an overall survival of 89% reported at 10 years. No severe treatment-related toxicity was observed.

    17. Sarcoma
      You have free access to this content
      Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma (pages 2315–2322)

      Rashmi Chugh, Thomas Wagner, Kent A. Griffith, Jeremy M.G. Taylor, Dafydd G. Thomas, Francis P. Worden, Kirsten M. Leu, Mark M. Zalupski and Laurence H. Baker

      Version of Record online: 26 APR 2007 | DOI: 10.1002/cncr.22669

      • original image
      • original image

      An assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma is presented.

    18. You have free access to this content
      High prevalence of p53 exon 4 mutations in soft tissue sarcoma (pages 2323–2333)

      Parimal Das, Dhanasekaran Kotilingam, Borys Korchin, Jeuhui Liu, Dihua Yu, Alexander J. Lazar, Raphael E. Pollock and Dina Lev

      Version of Record online: 11 APR 2007 | DOI: 10.1002/cncr.22680

      • original image
      • original image
      • original image

      p53 protein stabilization and p53 mutations frequently occur in soft tissue sarcoma; both correlate with worse outcome for soft tissue sarcoma patients. However, increased p53 protein expression is not necessarily due to p53 mutation and should, therefore, not be used clinically as the sole assay of p53 mutation. Better outcome prediction is achieved from combining p53 immunohistochemistry and p53 direct sequencing and, therefore, they should become the basis for these assessments.

    19. Discipline

      Medical Oncology
      You have free access to this content
      Economic burden of metastatic bone disease in the U.S. (pages 2334–2342)

      Kathy L. Schulman and Joseph Kohles

      Version of Record online: 20 APR 2007 | DOI: 10.1002/cncr.22678

      • original image
      • original image

      It is estimated that metastatic bone disease (MBD) affects 4,861,987 individuals annually in the U.S. This results in a national cost burden of 17% of the total direct medical costs incurred by oncology treatment, indicating the enormous impact of MBD on expenditures.

    20. Pediatric Oncology
      You have free access to this content
      Role of diagnostic and ablative minimally invasive surgery for pediatric malignancies (pages 2343–2348)

      Martin L. Metzelder, Joachim F. Kuebler, Akihiro Shimotakahara, Sylvia Glueer, Lorenz Grigull and Benno M. Ure

      Version of Record online: 20 APR 2007 | DOI: 10.1002/cncr.22696

      • original image
      • original image

      The objective of the study was to evaluate the diagnostic and ablative role of minimally invasive surgery (MIS) for pediatric cancer according to current tumor protocols. The results indicated that MIS is a reliable diagnostic tool for pediatric abdominal and thoracic malignancy. The role of ablative MIS in pediatric cancer remains limited.

    21. You have free access to this content
      Biallelic germline mutations of mismatch-repair genes : A possible cause for multiple pediatric malignancies (pages 2349–2356)

      Jan-Werner Poley, Anja Wagner, Monique M. C. P. Hoogmans, Fred H. Menko, Carli Tops, Johan M. Kros, Roel E. Reddingius, Hanne Meijers-Heijboer, Ernst J. Kuipers, Winand N. M. Dinjens and on behalf of the Rotterdam Initiative on Gastrointestinal Hereditary Tumors

      Version of Record online: 17 APR 2007 | DOI: 10.1002/cncr.22697

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The role of biallelic germline mutations in mismatch-repair genes was investigated in a cohort of pediatric oncology patients with multiple tumors. Of 15 patients, 2 possibly affected children could be identified.

    22. Disease Site

      Symptom Control and Palliative Care
      You have free access to this content
      Cost-effectiveness of influenza vaccination in working-age cancer patients (pages 2357–2364)

      Elenir B. C. Avritscher, Catherine D. Cooksley, Jane M. Geraci, Benjamin N. Bekele, Scott B. Cantor, Kenneth V. Rolston and Linda S. Elting

      Version of Record online: 24 APR 2007 | DOI: 10.1002/cncr.22670

      • original image
      • original image

      Despite the attenuated immune response of cancer patients to influenza vaccination, the inactivated influenza vaccine is cost-effective for working-age (ages 20–64 years) cancer patients diagnosed within the previous 5 years who have a life expectancy of ≥3 months. All working-age cancer patients who are within 5 years of cancer diagnosis and have a life expectancy of ≥3 months should be vaccinated against influenza.

    23. Discipline

      Symptom Control and Palliative Care
      You have free access to this content
      Opioid medications and longitudinal risk of delirium in hospitalized cancer patients (pages 2365–2373)

      Jean-David Gaudreau, Pierre Gagnon, Marc-André Roy, François Harel and Annie Tremblay

      Version of Record online: 27 APR 2007 | DOI: 10.1002/cncr.22665

      • original image

      Delirium is a highly prevalent psychiatric condition in oncology. Exposure to opioids during hospitalization is associated significantly with an increased longitudinal risk of delirium in hospitalized cancer patients.

    24. Translational Research
      You have free access to this content
      Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells (pages 2374–2382)

      Yan Yu, Qun Zhou, Yan Hang, Xuexian Bu and William Jia

      Version of Record online: 26 APR 2007 | DOI: 10.1002/cncr.22659

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      An investigation of the interaction between aPPD and estrogen receptors (ER) in human breast adenocarcinoma MCF-7 cells found that aPPD inhibits estrogen-stimulated gene expression and cell proliferation in ER-positive breast cancer cells. In addition, aPPD synergistically enhances cytotoxicity of tamoxifen in an ER-independent fashion, probably by down-regulating Akt activity.

  4. Correspondence

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 2384)

      Dawn Hershman and Alfred Neugut

      Version of Record online: 12 APR 2007 | DOI: 10.1002/cncr.22708

  5. Erratum

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      Erratum (pages 2385–2386)

      Version of Record online: 10 APR 2007 | DOI: 10.1002/cncr.22722

SEARCH

SEARCH BY CITATION